Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C

Norihiro Furusyo, Eiichi Ogawa, Makoto Nakamuta, Eiji Kajiwara, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Akira Kawano, Yuichi Tanabe, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Background & Aims This study was performed to evaluate the efficacy of a triple therapy in older Japanese patients; telaprevir (TVR) was added to pegylated interferon α2b and ribavirin. Methods This prospective study enrolled 120 genotype 1b patients with chronic hepatitis C who received 12 weeks of triple therapy followed by a 12-week dual therapy that included pegylated interferon α2b and ribavirin. Patients were categorized according to age: group A, 64 patients aged >60 and group B, 56 patients aged ≤60. Serum HCV RNA levels were monitored by COBAS TaqMan HCV test. Results The rates of undetectable HCV RNA at week 4 (rapid virological response, RVR) were 73.4% in group A and 73.2% in group B. No significant difference in sustained virological response (SVR) was found between groups A (76.6%) and B (83.9%) (p = 0.314). The SVR rates for patients with interleukin 28B (IL28B) (rs8099917) TT allele (89.4% and 91.9% for groups A and B) were significantly higher than for those with the IL28B TG/GG allele (41.2% and 68.4%, respectively) (both p <0.05). Multivariate analysis extracted IL28B TT and RVR as independent factors associated with SVR. Adverse effects resulted in treatment discontinuation by 12.5% in each group. Hemoglobin decrease significantly differed between groups A and B: the decrease to ≥100 g/L, to 85 - <100 g/L, and to <85 g/L, was 9.4%, 40.6%, and 50% in group A patients, respectively, and 41.1%, 25%, and 33.9% in group B patients, respectively (p = 0.0006). Conclusions TVR-based triple therapy can be successfully used to treat older patients with genotype 1b chronic hepatitis C.

Original languageEnglish
Pages (from-to)205-212
Number of pages8
JournalJournal of Hepatology
Volume59
Issue number2
DOIs
Publication statusPublished - Aug 1 2013

Fingerprint

Chronic Hepatitis C
Genotype
Interleukins
Ribavirin
Interferons
Alleles
RNA
Therapeutics
telaprevir
Hemoglobins
Multivariate Analysis
Age Groups
Prospective Studies
Serum

All Science Journal Classification (ASJC) codes

  • Hepatology

Cite this

Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. / Furusyo, Norihiro; Ogawa, Eiichi; Nakamuta, Makoto; Kajiwara, Eiji; Nomura, Hideyuki; Dohmen, Kazufumi; Takahashi, Kazuhiro; Satoh, Takeaki; Azuma, Koichi; Kawano, Akira; Tanabe, Yuichi; Kotoh, Kazuhiro; Shimoda, Shinji; Hayashi, Jun.

In: Journal of Hepatology, Vol. 59, No. 2, 01.08.2013, p. 205-212.

Research output: Contribution to journalArticle

Furusyo, N, Ogawa, E, Nakamuta, M, Kajiwara, E, Nomura, H, Dohmen, K, Takahashi, K, Satoh, T, Azuma, K, Kawano, A, Tanabe, Y, Kotoh, K, Shimoda, S & Hayashi, J 2013, 'Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C', Journal of Hepatology, vol. 59, no. 2, pp. 205-212. https://doi.org/10.1016/j.jhep.2013.03.020
Furusyo, Norihiro ; Ogawa, Eiichi ; Nakamuta, Makoto ; Kajiwara, Eiji ; Nomura, Hideyuki ; Dohmen, Kazufumi ; Takahashi, Kazuhiro ; Satoh, Takeaki ; Azuma, Koichi ; Kawano, Akira ; Tanabe, Yuichi ; Kotoh, Kazuhiro ; Shimoda, Shinji ; Hayashi, Jun. / Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. In: Journal of Hepatology. 2013 ; Vol. 59, No. 2. pp. 205-212.
@article{61b8e34a35804a1ba15e2c356a65d66e,
title = "Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C",
abstract = "Background & Aims This study was performed to evaluate the efficacy of a triple therapy in older Japanese patients; telaprevir (TVR) was added to pegylated interferon α2b and ribavirin. Methods This prospective study enrolled 120 genotype 1b patients with chronic hepatitis C who received 12 weeks of triple therapy followed by a 12-week dual therapy that included pegylated interferon α2b and ribavirin. Patients were categorized according to age: group A, 64 patients aged >60 and group B, 56 patients aged ≤60. Serum HCV RNA levels were monitored by COBAS TaqMan HCV test. Results The rates of undetectable HCV RNA at week 4 (rapid virological response, RVR) were 73.4{\%} in group A and 73.2{\%} in group B. No significant difference in sustained virological response (SVR) was found between groups A (76.6{\%}) and B (83.9{\%}) (p = 0.314). The SVR rates for patients with interleukin 28B (IL28B) (rs8099917) TT allele (89.4{\%} and 91.9{\%} for groups A and B) were significantly higher than for those with the IL28B TG/GG allele (41.2{\%} and 68.4{\%}, respectively) (both p <0.05). Multivariate analysis extracted IL28B TT and RVR as independent factors associated with SVR. Adverse effects resulted in treatment discontinuation by 12.5{\%} in each group. Hemoglobin decrease significantly differed between groups A and B: the decrease to ≥100 g/L, to 85 - <100 g/L, and to <85 g/L, was 9.4{\%}, 40.6{\%}, and 50{\%} in group A patients, respectively, and 41.1{\%}, 25{\%}, and 33.9{\%} in group B patients, respectively (p = 0.0006). Conclusions TVR-based triple therapy can be successfully used to treat older patients with genotype 1b chronic hepatitis C.",
author = "Norihiro Furusyo and Eiichi Ogawa and Makoto Nakamuta and Eiji Kajiwara and Hideyuki Nomura and Kazufumi Dohmen and Kazuhiro Takahashi and Takeaki Satoh and Koichi Azuma and Akira Kawano and Yuichi Tanabe and Kazuhiro Kotoh and Shinji Shimoda and Jun Hayashi",
year = "2013",
month = "8",
day = "1",
doi = "10.1016/j.jhep.2013.03.020",
language = "English",
volume = "59",
pages = "205--212",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C

AU - Furusyo, Norihiro

AU - Ogawa, Eiichi

AU - Nakamuta, Makoto

AU - Kajiwara, Eiji

AU - Nomura, Hideyuki

AU - Dohmen, Kazufumi

AU - Takahashi, Kazuhiro

AU - Satoh, Takeaki

AU - Azuma, Koichi

AU - Kawano, Akira

AU - Tanabe, Yuichi

AU - Kotoh, Kazuhiro

AU - Shimoda, Shinji

AU - Hayashi, Jun

PY - 2013/8/1

Y1 - 2013/8/1

N2 - Background & Aims This study was performed to evaluate the efficacy of a triple therapy in older Japanese patients; telaprevir (TVR) was added to pegylated interferon α2b and ribavirin. Methods This prospective study enrolled 120 genotype 1b patients with chronic hepatitis C who received 12 weeks of triple therapy followed by a 12-week dual therapy that included pegylated interferon α2b and ribavirin. Patients were categorized according to age: group A, 64 patients aged >60 and group B, 56 patients aged ≤60. Serum HCV RNA levels were monitored by COBAS TaqMan HCV test. Results The rates of undetectable HCV RNA at week 4 (rapid virological response, RVR) were 73.4% in group A and 73.2% in group B. No significant difference in sustained virological response (SVR) was found between groups A (76.6%) and B (83.9%) (p = 0.314). The SVR rates for patients with interleukin 28B (IL28B) (rs8099917) TT allele (89.4% and 91.9% for groups A and B) were significantly higher than for those with the IL28B TG/GG allele (41.2% and 68.4%, respectively) (both p <0.05). Multivariate analysis extracted IL28B TT and RVR as independent factors associated with SVR. Adverse effects resulted in treatment discontinuation by 12.5% in each group. Hemoglobin decrease significantly differed between groups A and B: the decrease to ≥100 g/L, to 85 - <100 g/L, and to <85 g/L, was 9.4%, 40.6%, and 50% in group A patients, respectively, and 41.1%, 25%, and 33.9% in group B patients, respectively (p = 0.0006). Conclusions TVR-based triple therapy can be successfully used to treat older patients with genotype 1b chronic hepatitis C.

AB - Background & Aims This study was performed to evaluate the efficacy of a triple therapy in older Japanese patients; telaprevir (TVR) was added to pegylated interferon α2b and ribavirin. Methods This prospective study enrolled 120 genotype 1b patients with chronic hepatitis C who received 12 weeks of triple therapy followed by a 12-week dual therapy that included pegylated interferon α2b and ribavirin. Patients were categorized according to age: group A, 64 patients aged >60 and group B, 56 patients aged ≤60. Serum HCV RNA levels were monitored by COBAS TaqMan HCV test. Results The rates of undetectable HCV RNA at week 4 (rapid virological response, RVR) were 73.4% in group A and 73.2% in group B. No significant difference in sustained virological response (SVR) was found between groups A (76.6%) and B (83.9%) (p = 0.314). The SVR rates for patients with interleukin 28B (IL28B) (rs8099917) TT allele (89.4% and 91.9% for groups A and B) were significantly higher than for those with the IL28B TG/GG allele (41.2% and 68.4%, respectively) (both p <0.05). Multivariate analysis extracted IL28B TT and RVR as independent factors associated with SVR. Adverse effects resulted in treatment discontinuation by 12.5% in each group. Hemoglobin decrease significantly differed between groups A and B: the decrease to ≥100 g/L, to 85 - <100 g/L, and to <85 g/L, was 9.4%, 40.6%, and 50% in group A patients, respectively, and 41.1%, 25%, and 33.9% in group B patients, respectively (p = 0.0006). Conclusions TVR-based triple therapy can be successfully used to treat older patients with genotype 1b chronic hepatitis C.

UR - http://www.scopus.com/inward/record.url?scp=84880277735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880277735&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2013.03.020

DO - 10.1016/j.jhep.2013.03.020

M3 - Article

C2 - 23542346

AN - SCOPUS:84880277735

VL - 59

SP - 205

EP - 212

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 2

ER -